|
Market Closed -
NYSE
16:02:15 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 106.20 USD | +1.56% |
|
+2.41% | -15.24% |
| 10-29 | Perrigo to sell infant formula business to MeridianMade for up to $175 million | RE |
| 10-29 | Perrigo to sell infant formula business to MeridianMade for up to $175 million | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 183,767 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -15.65% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 207,321 | 203,905 | 200,184 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -6.72% | -1.65% | -1.83% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 35.1x | 25.6x | 21.7x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.88x | 3.83x | 3.66x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -1.9x | 0.7x | 1.2x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.68x | 3.43x | 3.23x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.15x | 3.81x | 3.52x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.6x | 14.1x | 12.9x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.8x | 16x | 14.5x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.3x | 22.5x | 20.8x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.95% | 4.45% | 4.82% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.594 | 2.765 | 2.941 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.44% | 2.6% | 2.77% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.023 | 4.155 | 4.904 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 85.8% | 66.6% | 60% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 49,964 | 53,528 | 56,931 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,300 | 14,424 | 15,492 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,663 | 12,715 | 13,827 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 5,643 | 7,663 | 8,535 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,555 | 20,139 | 16,417 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 106.20 | 106.20 | 106.20 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 1/26/22 | 1/25/23 | 1/24/24 | 1/22/25 | 1/22/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.13x | 4.15x | 15.59x | 2.44% | 184B | |
| 24.35x | 4.53x | 15.49x | 1.24% | 112B | |
| 20.76x | 3.57x | 12.79x | 2.94% | 118B | |
| 32.34x | 3.11x | 12.55x | 2.2% | 94.58B | |
| 18.14x | 0.21x | 13.15x | 0.72% | 63.13B | |
| 31.66x | 7.9x | 20.3x | 1.25% | 55.66B | |
| 39.25x | 3.62x | 12.32x | 2.11% | 53.9B | |
| 37.34x | 9.27x | 25.93x | -.--% | 43.42B | |
| 44.54x | 3.36x | 12.49x | 0.52% | 34.68B | |
| 31.81x | 5.75x | 18.07x | -.--% | 30.69B | |
| Average | 31.53x | 4.55x | 15.87x | 1.34% | 79B | |
| Weighted average by Cap. | 30.20x | 4.21x | 15.24x | 1.76% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
